Markus Hecker
Corporate Officer/Principal at Ruprecht-Karls-Universität Heidelberg
Profile
Markus Hecker is the founder of Avontec GmbH, which was founded in 2001.
He held the title of Director-Supervisory Board from 2009 to 2010.
Dr. Hecker is currently working at Ruprecht-Karls-Universität Heidelberg as Director-Physiology & Pathophysiology since 2009.
Dr. Hecker has previously worked at the University of Freiburg, St. Bartholomew's Hospital, and Georgetown University as a Principal.
From 1996 to 2004, he worked at the University of Gottingen as a Principal.
Dr. Hecker obtained his doctorate degree from Universität Konstanz.
Markus Hecker active positions
| Companies | Position | Start |
|---|---|---|
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 05/11/2009 |
Former positions of Markus Hecker
| Companies | Position | End |
|---|---|---|
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Founder | 16/06/2010 |
| University of Gottingen | Corporate Officer/Principal | 01/01/2004 |
| University of Freiburg | Corporate Officer/Principal | - |
| St. Bartholomew's Hospital | Corporate Officer/Principal | - |
| Georgetown University | Corporate Officer/Principal | - |
Training of Markus Hecker
| Universität Konstanz | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Avontec GmbH
Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
| St. Bartholomew's Hospital |
- Stock Market
- Insiders
- Markus Hecker
